The goal of this clinical trial is to evaluate the safety and preliminary effectiveness of a new combination therapy in patients with advanced pancreatic cancer.
The main questions it aims to answer are:
1. Is the combination of the peptide nanovaccine (ONVAX-01), an anti-PD-1 antibody, and chemotherapy safe and well-tolerated? 2. Does this combination treatment help shrink tumors or stop the progression of advanced pancreatic cancer?
Participants will be asked to:
1. Receive doses of the peptide nanovaccine (ONVAX-01). 2. Receive intravenous infusions of an anti-PD-1 antibody and standard chemotherapy. 3. Undergo regular physical exams, blood tests, and imaging scans (such as CT or MRI) to monitor their health and the tumor's response to the treatment.
• Age between 18 and 75 years (inclusive).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histologically confirmed, KRAS-mutated, unresectable metastatic pancreatic ductal adenocarcinoma (PDAC).
Documented disease progression after at least one prior line of systemic therapy.
• Receipt of anti-tumor chemotherapy, radiotherapy, or immunotherapy within 2 weeks prior to the first dose of the study vaccine.
History of other malignancies, except adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, non-muscle invasive bladder cancer (Ta and TIS), or other malignancies curatively treated at least 5 years prior to enrollment.
Uncontrolled concomitant diseases, including but not limited to active bacterial or fungal infections, symptomatic congestive heart failure, unstable angina, or cardiac arrhythmias.
Prior treatment with any antibody or drug targeting T-cell co-regulatory proteins (immune checkpoints), such as anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-OX-40, anti-CD137, anti-TIM-3, or anti-LAG-3 antibodies.
Single group
ONVAX-01 plus Anti-PD-1 and Chemotherapy
DrugThe peptide nanovaccine (ONVAX-01) is administered via subcutaneous (SC) or intradermal (ID) injection, while the anti-PD-1 antibody and chemotherapy regimens are administered via intravenous (IV) infusion.
Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Objective Response Rate (ORR)
Disease Control Rate (DCR)
Progression-Free Survival (PFS)
Overall Survival (OS)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
